120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
植物来源细胞外囊泡样颗粒的稳定性挑战与工程化策略：转化视角
Authors Li H , Yan Y , Lin M , Wang S , Su Y, Guo J , Lu Y , Chen X, Zheng D
Received 30 May 2025
Accepted for publication 31 December 2025
Published 6 February 2026 Volume 2026:21 543674
DOI https://doi.org/10.2147/IJN.S543674
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Krishna Nune
Hengyi Li,1,* Yuxiang Yan,1,2,* Meifang Lin,1,2,* Shijie Wang,1 Yating Su,1,2 Jinhan Guo,1,2 Youguang Lu,1,2 Xiaohang Chen,1,2 Dali Zheng1
1Fujian Key Laboratory of Oral Diseases, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, People’s Republic of China; 2Department of Preventive Dentistry, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Dali Zheng; Xiaohang Chen, Email dalizheng@fjmu.edu.cn; kqyx__cxh@163.com
Abstract: Plant-derived extracellular vesicle-like particles (PD-EVLPs), composed of a phospholipid bilayer enriched with lipids, proteins, metabolites, and RNA, have emerged as promising therapeutic agents with intrinsic bioactivity (eg, anti-inflammatory and wound healing activities) as well as biocompatible nanocarriers. However, before their clinical translation, a key challenge lies in ensuring their stability in biological environments and achieving effective accumulation at disease sites. On one hand, the lack of standardized isolation protocols and preservation strategies where non-standardized methods compromise yield-purity balance, freeze-thaw cycles induce lipid rearrangements that lead to vesicle fusion, and lyophilization-induced ice crystals disrupt membrane integrity, poses a significant barrier to maintaining the dispersity, structural integrity, and purity of PD-EVLPs affecting their ex vivo stability. On the other hand, extreme conditions in gastric and intestinal fluids during administration can easily cause PD-EVLPs to degrade and their content to leak, while in vivo circulation necessitates avoiding rapid immune clearance in order to accumulate at target sites, further challenging their stability and bioavailability. In this review, we comprehensively evaluate the entire PD-EVLPs pipeline from preparation to application, dissecting potential stability concerns at each stage, including isolation, storage conditions, structural composition, and administration routes. We also explore the contribution of engineering strategies to enhancing PD-EVLPs stability while considering potential risks associated with these modifications. By establishing a comprehensive framework, we aim to provide concrete guidance for standardizing PD-EVLPs preparation protocols and designing preclinical studies, thereby streamlining their translation from bench to bedside.
Plain Language Summary: From standardized isolation to preservation: Analyzing the impact of PD-EVLPs’ preparation and storage on their stability, paving the way for industrial-scale production.Decoding structure and composition: Unveiling how the lipid bilayer structure and components of PD-EVLPs influence their stability, ensuring their efficacy in drug delivery.Engineering modifications and biomimicry: Exploring strategies to overcome the intrinsic stability limitations of PD-EVLPs and enhance their functionality for in vivo applications.
Keywords: plant-derived extracellular vesicle-like particles, stability, engineered modification, isolation, administration
1Fujian Key Laboratory of Oral Diseases, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, People’s Republic of China; 2Department of Preventive Dentistry, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Dali Zheng; Xiaohang Chen, Email dalizheng@fjmu.edu.cn; kqyx__cxh@163.com
Abstract: Plant-derived extracellular vesicle-like particles (PD-EVLPs), composed of a phospholipid bilayer enriched with lipids, proteins, metabolites, and RNA, have emerged as promising therapeutic agents with intrinsic bioactivity (eg, anti-inflammatory and wound healing activities) as well as biocompatible nanocarriers. However, before their clinical translation, a key challenge lies in ensuring their stability in biological environments and achieving effective accumulation at disease sites. On one hand, the lack of standardized isolation protocols and preservation strategies where non-standardized methods compromise yield-purity balance, freeze-thaw cycles induce lipid rearrangements that lead to vesicle fusion, and lyophilization-induced ice crystals disrupt membrane integrity, poses a significant barrier to maintaining the dispersity, structural integrity, and purity of PD-EVLPs affecting their ex vivo stability. On the other hand, extreme conditions in gastric and intestinal fluids during administration can easily cause PD-EVLPs to degrade and their content to leak, while in vivo circulation necessitates avoiding rapid immune clearance in order to accumulate at target sites, further challenging their stability and bioavailability. In this review, we comprehensively evaluate the entire PD-EVLPs pipeline from preparation to application, dissecting potential stability concerns at each stage, including isolation, storage conditions, structural composition, and administration routes. We also explore the contribution of engineering strategies to enhancing PD-EVLPs stability while considering potential risks associated with these modifications. By establishing a comprehensive framework, we aim to provide concrete guidance for standardizing PD-EVLPs preparation protocols and designing preclinical studies, thereby streamlining their translation from bench to bedside.
Plain Language Summary: From standardized isolation to preservation: Analyzing the impact of PD-EVLPs’ preparation and storage on their stability, paving the way for industrial-scale production.Decoding structure and composition: Unveiling how the lipid bilayer structure and components of PD-EVLPs influence their stability, ensuring their efficacy in drug delivery.Engineering modifications and biomimicry: Exploring strategies to overcome the intrinsic stability limitations of PD-EVLPs and enhance their functionality for in vivo applications.
Keywords: plant-derived extracellular vesicle-like particles, stability, engineered modification, isolation, administration